ASCEND-D
2021
Anaemia Studies in CKD: Daprodustat — Dialysis
In 2,964 dialysis patients with anaemia, the oral HIF prolyl-hydroxylase inhibitor daprodustat was non-inferior for haemoglobin and cardiovascular safety compared with erythropoiesis-stimulating agents.
Result
Efficacy: Change in haemoglobin; major adverse cardiovascular eventsHR 0.93 (95% CI 0.81-1.07)
Below 1 favours daprodustat, above 1 favours erythropoiesis-stimulating agents.
Also reported: Haemoglobin non-inferior;
- Subtopic
- HIF-PHI anaemia
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Cited in
- KDIGO 2026 Anaemia in CKD
- Source
- Singh AK, et al. N Engl J Med. 2021;385(25):2325-2335.doi 10.1056/NEJMoa2113379
Discussion & critique
Supported approval of an oral anaemia agent for dialysis patients; non-dialysis use is more cautious.